Intrinsic value of Ocular Therapeutix - OCUL

Previous Close

$5.29

  Intrinsic Value

$0.23

stock screener

  Rating & Target

str. sell

-96%

Previous close

$5.29

 
Intrinsic value

$0.23

 
Up/down potential

-96%

 
Rating

str. sell

We calculate the intrinsic value of OCUL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.2

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  47.90
  43.61
  39.75
  36.27
  33.15
  30.33
  27.80
  25.52
  23.47
  21.62
  19.96
  18.46
  17.12
  15.90
  14.81
  13.83
  12.95
  12.15
  11.44
  10.80
  10.22
  9.69
  9.22
  8.80
  8.42
  8.08
  7.77
  7.49
  7.25
  7.02
Revenue, $m
  3
  4
  6
  8
  10
  13
  17
  22
  27
  33
  39
  46
  54
  63
  72
  82
  93
  104
  116
  128
  141
  155
  169
  184
  200
  216
  233
  250
  268
  287
Variable operating expenses, $m
  68
  98
  137
  187
  249
  324
  414
  520
  642
  780
  936
  1,109
  1,299
  1,505
  1,728
  1,967
  2,222
  2,492
  2,777
  3,077
  3,391
  3,720
  4,063
  4,421
  4,793
  5,181
  5,583
  6,002
  6,436
  6,888
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  68
  98
  137
  187
  249
  324
  414
  520
  642
  780
  936
  1,109
  1,299
  1,505
  1,728
  1,967
  2,222
  2,492
  2,777
  3,077
  3,391
  3,720
  4,063
  4,421
  4,793
  5,181
  5,583
  6,002
  6,436
  6,888
Operating income, $m
  -65
  -94
  -131
  -179
  -238
  -310
  -397
  -498
  -615
  -748
  -897
  -1,063
  -1,245
  -1,443
  -1,656
  -1,885
  -2,129
  -2,388
  -2,662
  -2,949
  -3,250
  -3,565
  -3,894
  -4,237
  -4,594
  -4,965
  -5,351
  -5,752
  -6,168
  -6,601
EBITDA, $m
  -63
  -91
  -127
  -174
  -231
  -301
  -385
  -483
  -596
  -725
  -870
  -1,031
  -1,207
  -1,399
  -1,607
  -1,829
  -2,066
  -2,317
  -2,582
  -2,860
  -3,153
  -3,458
  -3,777
  -4,110
  -4,456
  -4,816
  -5,190
  -5,579
  -5,983
  -6,403
Interest expense (income), $m
  1
  2
  2
  4
  5
  7
  10
  13
  17
  21
  27
  32
  39
  46
  54
  63
  73
  83
  94
  105
  117
  130
  143
  157
  172
  187
  203
  219
  236
  254
  272
Earnings before tax, $m
  -67
  -96
  -135
  -184
  -245
  -320
  -410
  -515
  -636
  -774
  -930
  -1,102
  -1,291
  -1,497
  -1,719
  -1,958
  -2,212
  -2,482
  -2,767
  -3,066
  -3,380
  -3,708
  -4,051
  -4,408
  -4,780
  -5,167
  -5,570
  -5,988
  -6,422
  -6,874
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -67
  -96
  -135
  -184
  -245
  -320
  -410
  -515
  -636
  -774
  -930
  -1,102
  -1,291
  -1,497
  -1,719
  -1,958
  -2,212
  -2,482
  -2,767
  -3,066
  -3,380
  -3,708
  -4,051
  -4,408
  -4,780
  -5,167
  -5,570
  -5,988
  -6,422
  -6,874

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  29
  41
  58
  79
  105
  136
  174
  219
  270
  328
  394
  467
  547
  634
  727
  828
  935
  1,049
  1,169
  1,295
  1,427
  1,566
  1,710
  1,861
  2,017
  2,180
  2,350
  2,526
  2,709
  2,899
Adjusted assets (=assets-cash), $m
  29
  41
  58
  79
  105
  136
  174
  219
  270
  328
  394
  467
  547
  634
  727
  828
  935
  1,049
  1,169
  1,295
  1,427
  1,566
  1,710
  1,861
  2,017
  2,180
  2,350
  2,526
  2,709
  2,899
Revenue / Adjusted assets
  0.103
  0.098
  0.103
  0.101
  0.095
  0.096
  0.098
  0.100
  0.100
  0.101
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
  0.099
Average production assets, $m
  10
  14
  20
  27
  36
  47
  59
  75
  92
  112
  134
  159
  187
  216
  248
  283
  319
  358
  399
  442
  487
  534
  584
  635
  689
  744
  802
  862
  925
  990
Working capital, $m
  -11
  -16
  -22
  -30
  -40
  -52
  -66
  -83
  -103
  -125
  -150
  -178
  -208
  -241
  -277
  -315
  -356
  -399
  -445
  -493
  -544
  -596
  -651
  -709
  -768
  -830
  -895
  -962
  -1,032
  -1,104
Total debt, $m
  20
  31
  46
  65
  88
  117
  151
  191
  237
  290
  349
  414
  486
  564
  649
  739
  836
  938
  1,046
  1,160
  1,279
  1,403
  1,533
  1,669
  1,810
  1,957
  2,109
  2,268
  2,432
  2,603
Total liabilities, $m
  26
  37
  52
  71
  94
  123
  157
  197
  243
  296
  355
  420
  492
  570
  655
  745
  842
  944
  1,052
  1,166
  1,285
  1,409
  1,539
  1,675
  1,816
  1,962
  2,115
  2,273
  2,438
  2,609
Total equity, $m
  3
  4
  6
  8
  10
  14
  17
  22
  27
  33
  39
  47
  55
  63
  73
  83
  94
  105
  117
  130
  143
  157
  171
  186
  202
  218
  235
  253
  271
  290
Total liabilities and equity, $m
  29
  41
  58
  79
  104
  137
  174
  219
  270
  329
  394
  467
  547
  633
  728
  828
  936
  1,049
  1,169
  1,296
  1,428
  1,566
  1,710
  1,861
  2,018
  2,180
  2,350
  2,526
  2,709
  2,899
Debt-to-equity ratio
  7.010
  7.610
  8.010
  8.270
  8.450
  8.580
  8.670
  8.740
  8.790
  8.830
  8.850
  8.880
  8.900
  8.910
  8.920
  8.930
  8.940
  8.950
  8.950
  8.960
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -67
  -96
  -135
  -184
  -245
  -320
  -410
  -515
  -636
  -774
  -930
  -1,102
  -1,291
  -1,497
  -1,719
  -1,958
  -2,212
  -2,482
  -2,767
  -3,066
  -3,380
  -3,708
  -4,051
  -4,408
  -4,780
  -5,167
  -5,570
  -5,988
  -6,422
  -6,874
Depreciation, amort., depletion, $m
  2
  3
  4
  5
  7
  9
  12
  15
  18
  22
  27
  32
  37
  43
  50
  57
  64
  72
  80
  88
  97
  107
  117
  127
  138
  149
  160
  172
  185
  198
Funds from operations, $m
  -65
  -93
  -131
  -179
  -238
  -311
  -398
  -500
  -618
  -752
  -903
  -1,070
  -1,254
  -1,454
  -1,670
  -1,901
  -2,148
  -2,410
  -2,687
  -2,978
  -3,283
  -3,601
  -3,934
  -4,281
  -4,643
  -5,019
  -5,409
  -5,815
  -6,237
  -6,676
Change in working capital, $m
  -4
  -5
  -6
  -8
  -10
  -12
  -14
  -17
  -20
  -22
  -25
  -28
  -30
  -33
  -36
  -38
  -41
  -43
  -46
  -48
  -50
  -53
  -55
  -57
  -60
  -62
  -65
  -67
  -70
  -72
Cash from operations, $m
  -62
  -89
  -125
  -171
  -228
  -299
  -384
  -483
  -598
  -730
  -878
  -1,042
  -1,223
  -1,421
  -1,634
  -1,863
  -2,108
  -2,367
  -2,641
  -2,930
  -3,232
  -3,549
  -3,879
  -4,224
  -4,583
  -4,956
  -5,345
  -5,748
  -6,168
  -6,603
Maintenance CAPEX, $m
  -1
  -2
  -3
  -4
  -5
  -7
  -9
  -12
  -15
  -18
  -22
  -27
  -32
  -37
  -43
  -50
  -57
  -64
  -72
  -80
  -88
  -97
  -107
  -117
  -127
  -138
  -149
  -160
  -172
  -185
New CAPEX, $m
  -3
  -4
  -6
  -7
  -9
  -11
  -13
  -15
  -18
  -20
  -22
  -25
  -27
  -30
  -32
  -34
  -37
  -39
  -41
  -43
  -45
  -47
  -49
  -51
  -53
  -56
  -58
  -60
  -62
  -65
Cash from investing activities, $m
  -4
  -6
  -9
  -11
  -14
  -18
  -22
  -27
  -33
  -38
  -44
  -52
  -59
  -67
  -75
  -84
  -94
  -103
  -113
  -123
  -133
  -144
  -156
  -168
  -180
  -194
  -207
  -220
  -234
  -250
Free cash flow, $m
  -66
  -95
  -133
  -182
  -243
  -317
  -406
  -510
  -631
  -768
  -922
  -1,094
  -1,282
  -1,488
  -1,709
  -1,947
  -2,201
  -2,470
  -2,754
  -3,052
  -3,366
  -3,693
  -4,036
  -4,392
  -4,764
  -5,150
  -5,551
  -5,969
  -6,403
  -6,853
Issuance/(repayment) of debt, $m
  2
  11
  15
  19
  23
  29
  34
  40
  46
  53
  59
  65
  72
  78
  84
  91
  96
  102
  108
  114
  119
  125
  130
  135
  141
  147
  153
  158
  165
  171
Issuance/(repurchase) of shares, $m
  74
  97
  136
  186
  248
  324
  414
  519
  641
  780
  936
  1,109
  1,299
  1,506
  1,729
  1,968
  2,223
  2,493
  2,779
  3,079
  3,393
  3,722
  4,066
  4,424
  4,796
  5,184
  5,587
  6,005
  6,441
  6,893
Cash from financing (excl. dividends), $m  
  76
  108
  151
  205
  271
  353
  448
  559
  687
  833
  995
  1,174
  1,371
  1,584
  1,813
  2,059
  2,319
  2,595
  2,887
  3,193
  3,512
  3,847
  4,196
  4,559
  4,937
  5,331
  5,740
  6,163
  6,606
  7,064
Total cash flow (excl. dividends), $m
  10
  14
  18
  23
  29
  35
  42
  49
  57
  65
  73
  81
  88
  96
  104
  111
  119
  126
  133
  140
  147
  153
  160
  167
  174
  181
  188
  195
  203
  211
Retained Cash Flow (-), $m
  -74
  -97
  -136
  -186
  -248
  -324
  -414
  -519
  -641
  -780
  -936
  -1,109
  -1,299
  -1,506
  -1,729
  -1,968
  -2,223
  -2,493
  -2,779
  -3,079
  -3,393
  -3,722
  -4,066
  -4,424
  -4,796
  -5,184
  -5,587
  -6,005
  -6,441
  -6,893
Prev. year cash balance distribution, $m
  30
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -34
  -84
  -118
  -163
  -219
  -288
  -372
  -470
  -585
  -716
  -863
  -1,028
  -1,210
  -1,409
  -1,625
  -1,857
  -2,104
  -2,367
  -2,646
  -2,939
  -3,247
  -3,569
  -3,906
  -4,257
  -4,623
  -5,003
  -5,399
  -5,810
  -6,238
  -6,682
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -33
  -77
  -103
  -134
  -170
  -209
  -251
  -294
  -336
  -375
  -410
  -439
  -460
  -473
  -477
  -472
  -458
  -436
  -407
  -373
  -336
  -296
  -256
  -217
  -180
  -146
  -116
  -90
  -68
  -50
Current shareholders' claim on cash, %
  50.0
  7.4
  1.1
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

FINANCIAL RATIOS  of  Ocular Therapeutix (OCUL)

Valuation Ratios
P/E Ratio -2.9
Price to Sales 66.2
Price to Book 2.5
Price to Tangible Book
Price to Cash Flow -3.9
Price to Free Cash Flow -3.7
Growth Rates
Sales Growth Rate 0%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 34
Current Ratio 0
LT Debt to Equity 26.9%
Total Debt to Equity 30.8%
Interest Coverage -44
Management Effectiveness
Return On Assets -47.6%
Ret/ On Assets - 3 Yr. Avg. -48.9%
Return On Total Capital -52%
Ret/ On T. Cap. - 3 Yr. Avg. -53.5%
Return On Equity -63.4%
Return On Equity - 3 Yr. Avg. -65.1%
Asset Turnover 0
Profitability Ratios
Gross Margin 50%
Gross Margin - 3 Yr. Avg. 66.7%
EBITDA Margin -2150%
EBITDA Margin - 3 Yr. Avg. -2250%
Operating Margin -2150%
Oper. Margin - 3 Yr. Avg. -2250%
Pre-Tax Margin -2250%
Pre-Tax Margin - 3 Yr. Avg. -2383.3%
Net Profit Margin -2250%
Net Profit Margin - 3 Yr. Avg. -2383.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

OCUL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the OCUL stock intrinsic value calculation we used $1.923 million for the last fiscal year's total revenue generated by Ocular Therapeutix. The default revenue input number comes from 0001 income statement of Ocular Therapeutix. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our OCUL stock valuation model: a) initial revenue growth rate of 47.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for OCUL is calculated based on our internal credit rating of Ocular Therapeutix, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Ocular Therapeutix.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of OCUL stock the variable cost ratio is equal to 2400%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for OCUL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 11.2% for Ocular Therapeutix.

Corporate tax rate of 27% is the nominal tax rate for Ocular Therapeutix. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the OCUL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for OCUL are equal to 344.8%.

Life of production assets of 4.2 years is the average useful life of capital assets used in Ocular Therapeutix operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for OCUL is equal to -384.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $26.147 million for Ocular Therapeutix - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 29.057 million for Ocular Therapeutix is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Ocular Therapeutix at the current share price and the inputted number of shares is $0.2 billion.

RELATED COMPANIES Price Int.Val. Rating
CRY CryoLife 28.70 19.35  sell
BVX Bovie Medical 6.05 0.15  str.sell
REGN Regeneron Phar 342.10 335.37  hold
ADVM Adverum Biotec 3.63 0.72  str.sell
OPHT Ophthotech 2.03 0.26  str.sell

COMPANY NEWS

▶ Ocular Therapeutix: 3Q Earnings Snapshot   [05:36PM  Associated Press]
▶ Who Owns Ocular Therapeutix Inc (NASDAQ:OCUL)?   [Oct-11-18 12:57PM  Simply Wall St.]
▶ Here's Why Ocular Therapeutix Jumped 21.6% in August   [Sep-10-18 12:36PM  Motley Fool]
▶ Ocular Therapeutix: 2Q Earnings Snapshot   [04:17PM  Associated Press]
▶ Ocular Therapeutix Announces NDA Resubmission of DEXTENZA   [Jun-29-18 08:00AM  Business Wire]
▶ 5 Clinical-Stage Biotech Stocks to Buy Under $10   [May-29-18 10:24AM  InvestorPlace]
▶ Ocular Therapeutix: 1Q Earnings Snapshot   [May-08-18 05:10PM  Associated Press]
▶ Biotechs Take the Lead This Morning   [10:29AM  TheStreet.com]
▶ Ocular Therapeutix Inc (NASDAQ:OCUL): Are Analysts Optimistic?   [Mar-15-18 08:30PM  Simply Wall St.]
▶ Under SEC scrutiny, Bedfords Ocular Therapeutix plans FDA do-over   [Mar-08-18 01:00PM  American City Business Journals]
▶ Ocular Therapeutix reports 4Q loss   [09:23AM  Associated Press]
▶ Top 3 Stocks Insiders Are Buying   [Feb-21-18 08:02AM  Simply Wall St.]
▶ Benzinga Pro's 4 Stocks To Watch Today   [Jan-25-18 09:11AM  Benzinga]
▶ Ocular Therapeutix Provides Legal Update   [04:05PM  Business Wire]
▶ Is It Too Late To Buy Ocular Therapeutix Inc (NASDAQ:OCUL)?   [Dec-13-17 04:54PM  Simply Wall St.]
▶ Ocular Therapeutix reports 3Q loss   [Nov-07-17 05:25PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.